Plasma mediators in patients with severe COVID-19 cause lung endothelial barrier failure

Affiliations

• ¹ Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany.
• ² Dept of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany.
• ³ Berlin Institute of Health (BIH), Berlin, Germany.
• ⁴ Max Delbrück Center for Molecular Medicine, Berlin, Germany.
• ⁵ German Center for Lung Research (DZL), Germany.
• ⁶ Dept of General, Visceral, Vascular and Thoracic Surgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany.
• ⁷ Lungenklinik Heckeshorn, HELIOS Klinikum Emil von Behring, Berlin, Germany.
• ⁸ Vivantes Netzwerk für Gesundheit, Klinikum Neukölln, Klinik für Thoraxchirurgie, Berlin, Germany.
• ⁹ Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany.
• ¹⁰ German Centre for Infection Research (DZIF), Germany.
• ¹¹ These authors contributed equally to this study.
• ¹² Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany [email protected].
• ¹³ The Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada.
• ¹⁴ Depts. of Surgery and Physiology, University of Toronto, Toronto, ON, Canada.
• ¹⁵ German Centre for Cardiovascular Research (DZHK), Germany.